Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYL-1401H vs Neulasta in breast cancer patients receiving TAC chemotherapy
2014-002324-27Phase 3Completed
- Sponsor
- Mylan
- Start
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegfilgrastim in neutropenia (2 arms), sponsored by Mylan. Primary endpoint: Duration of severe neutropenia in Cycle 1. Started Dec 2014; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on 2014-002324-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002324-27.